Candriam SCA’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.32M | Buy |
675,085
+224,650
| +50% | +$2.1M | 0.04% | 315 |
|
|
2025
Q1 | $5.53M | Sell |
450,435
-96,730
| -18% | -$1.19M | 0.03% | 312 |
|
|
2024
Q4 | $7.23M | Sell |
547,165
-451,454
| -45% | -$5.97M | 0.04% | 304 |
|
|
2024
Q3 | $19.2M | Buy |
998,619
+28,513
| +3% | +$549K | 0.11% | 184 |
|
|
2024
Q2 | $19.9M | Sell |
970,106
-74,926
| -7% | -$1.54M | 0.12% | 169 |
|
|
2024
Q1 | $24.9M | Buy |
1,045,032
+24,000
| +2% | +$571K | 0.16% | 139 |
|
|
2023
Q4 | $22.1M | Buy |
1,021,032
+781,022
| +325% | +$16.9M | 0.15% | 151 |
|
|
2023
Q3 | $3.48M | Hold |
240,010
| – | – | 0.02% | 357 |
|
|
2023
Q2 | $5.02M | Sell |
240,010
-14,864
| -6% | -$311K | 0.04% | 331 |
|
|
2023
Q1 | $4.95M | Buy |
+254,874
| New | +$4.95M | 0.03% | 366 |
|
|
2021
Q2 | – | Sell |
-25,671
| Closed | -$548K | – | 935 |
|
|
2021
Q1 | $548K | Hold |
25,671
| – | – | ﹤0.01% | 703 |
|
|
2020
Q4 | $571K | Sell |
25,671
-332,701
| -93% | -$7.4M | ﹤0.01% | 716 |
|
|
2020
Q3 | $5.29M | Buy |
358,372
+10,914
| +3% | +$161K | 0.05% | 345 |
|
|
2020
Q2 | $5.15M | Buy |
+347,458
| New | +$5.15M | 0.05% | 324 |
|
|
2018
Q1 | – | Sell |
-70,000
| Closed | -$613K | – | 786 |
|
|
2017
Q4 | $613K | Buy |
+70,000
| New | +$613K | 0.01% | 647 |
|